3 - OSR Holdings, Inc. (0001840425) (Issuer)

3 - OSR Holdings, Inc. (0001840425) (Issuer)

3 - OSR Holdings, Inc. (0001840425) (Issuer)

3 - OSR Holdings, Inc. (0001840425) (Issuer)

3 - OSR Holdings, Inc. (0001840425) (Issuer)

4 - OSR Holdings, Inc. (0001840425) (Issuer)

4 - OSR Holdings, Inc. (0001840425) (Issuer)

3 - OSR Holdings, Inc. (0001840425) (Issuer)

3 - OSR Holdings, Inc. (0001840425) (Issuer)

3 - Bellevue Life Sciences Acquisition Corp. (0001840425) (Issuer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

25-NSE - OSR Holdings, Inc. (0001840425) (Subject)

425 - Bellevue Life Sciences Acquisition Corp. (0001840425) (Subject)

8-K - Bellevue Life Sciences Acquisition Corp. (0001840425) (Filer)

EFFECT - Bellevue Life Sciences Acquisition Corp. (0001840425) (Filer)

424B3 - Bellevue Life Sciences Acquisition Corp. (0001840425) (Filer)

S-4/A - Bellevue Life Sciences Acquisition Corp. (0001840425) (Filer)

S-4/A - Bellevue Life Sciences Acquisition Corp. (0001840425) (Filer)

8-K - Bellevue Life Sciences Acquisition Corp. (0001840425) (Filer)

8-K - Bellevue Life Sciences Acquisition Corp. (0001840425) (Filer)

BELLEVUE, Wash. and ZUG, Switzerland, July 8, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced the official roadmap for a targeted $50 million security token offering (STO) planned for launch in the second half of 2025 under Regulation D of the U.S. Securities Act. The token, with the working title OSRT, will be a securitized digital asset representing OSR Holdings' equity exposure and is designed to align with the company's blockchain-based capital strategy. As part of this roadmap

SEOUL, South Korea and ZUG, Switzerland, May 22, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a public company dedicated to advancing innovation in healthcare and wellness, announced today that it has entered into a Memorandum of Understanding (MOU) with BCM Europe AG, its major shareholder, and Taekwondo Cooperative (TKD Coop), a global Taekwondo community organization, to explore the joint development of a security token, provisionally named the "OSRH Token". The initiative aims to enhance access to crypto-based liquidity and provide a basis for OSRH to launch crypto treasury strategies.

OSR Holdings, Inc. to Begin Trading on the Nasdaq Stock Market LLC on Tuesday, February 18, 2025Under the symbol "OSRH" SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (formerly Bellevue Life Sciences Acquisition Corp. (the "Company")) and OSR Holdings Co., Ltd. ("OSR") announced today the completion of their business combination (the "Business Combination"). The Company now operates as "OSR Holdings, Inc." following the successful completion of the Business Combination.  Beginning on Tuesday, February 18, 2025, the common stock and warrants of the Company

SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- Bellevue Life Sciences Acquisition Corp. ("BLAC") announced today the approval of each of the proposals presented at the special meeting of its stockholders (the "Special Meeting") held today, including the proposal for the business combination with OSR Holdings Co., Ltd. (the "Transaction").  BLAC expects the Transaction to close following receipt of foreign investment approval from the Industrial Bank of Korea, which is expected on February 14, 2025.  Following the Special Meeting, BLAC filed its Amended and Restated Certific

BELLEVUE, Wash., May 13, 2024 /PRNewswire/ -- As previously announced, on May 10, 2024, Bellevue Life Sciences Acquisitions Corp. (NASDAQ:BLAC) ("BLAC") convened a special meeting of stockholders (the "Special Meeting"), adjourned the Special Meeting without any business being conducted, and announced that the Special Meeting will be reconvened at 9:00 a.m. Pacific time on Tuesday, May 14, 2024, at 925 Fourth Avenue, Suite 2900, Seattle, WA 98104. At the reconvened Special Meeting, stockholders will consider and vote upon the matters described in BLAC's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on April 26, 2024 (the "Proxy Statement"). BL

SEOUL, South Korea, April 22, 2024 /PRNewswire/ -- OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech firm with a pipeline of immuno-oncology drug candidates, to share technology and clinical development resources and launch a strategic collaboration between the two companies. Through the MOU, the two companies will explore various ways to collaborate to create synergies between current platform technologies and new drug candidates. OSR Holdings was established in 2019 in So

BELLEVUE, Wash. and SEOUL, South Korea, Nov. 16, 2023 /PRNewswire/ -- Bellevue Life Sciences Acquisition Corp. (NASDAQ:BLAC), a publicly traded special purpose acquisition company ("BLAC"), and OSR Holdings Co., Ltd. ("OSR Holdings"), a global healthcare holding company, announced today that they have entered into a business combination agreement. Upon closing of the transaction, outstanding shares of OSR Holdings held by certain of the holders of OSR Holdings' common stock will be exchanged for newly issued shares of BLAC common stock. Following the closing, BLAC will own at least 60% of the outstanding shares of OSR Holdings (and have the right to acquire the remainder of the shares on or

OSR Holdings expected to be public in the fourth quarter of 2023 BELLEVUE, Wash. and SEOUL, South Korea, July 11, 2023 /PRNewswire/ -- Bellevue Life Sciences Acquisition Corp. (NASDAQ:BLAC), a publicly traded special purpose acquisition company ("BLAC"), and OSR Holdings, Ltd. ("OSR Holdings"), a global healthcare holding company, announced today that they have entered into an exclusive, non-binding letter of intent, with the goal of completing a business combination in the fourth quarter of 2023, resulting in OSR Holdings becoming a publicly traded company. BLAC and OSR Holdings expect to finalize their definitive agreement with respect to the proposed business combination in the coming wee

SC 13G - Bellevue Life Sciences Acquisition Corp. (0001840425) (Subject)

SC 13G/A - Bellevue Life Sciences Acquisition Corp. (0001840425) (Subject)

SC 13G - Bellevue Life Sciences Acquisition Corp. (0001840425) (Subject)

SC 13G/A - Bellevue Life Sciences Acquisition Corp. (0001840425) (Subject)